The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

To treat depression, the tech magnate has said he'd rather use ketamine, a dissociative anesthetic, than traditional antidepressants.

Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Free Report) traded up 3.2% on Friday . The company traded as high as $0.96 and last traded at $0.96. 263,496 shares were traded during trading, an increase ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have ...

This study is the first to inject repeated doses of stem cells intravenously into patients who have heart failure due to a heart attack or coronary artery disease.

Astellas Pharma (ALPMY) and Sangamo (SGMO) announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s ...

The BIRCH trial will enroll a total of 32 patients, with 24 receiving BIOX-101, and 8 standard-of-care treatment. In the study, BIOX-101 is administered intravenously within the first hours from onset ...

Akamis Bio, a clinical-stage oncology company, has raised $60 million in Series A funding that will drive continued development of NG-350A, a new gene therapy based on its proprietary tumor ...

This dosage is so high it must be administered intravenously, not through dietary sources or supplements. The results were remarkable, according to Dr. Benga. "By getting a significant higher ...